Christopher Moriates
University of Texas at Austin
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher Moriates.
JAMA Internal Medicine | 2014
Tanner J. Caverly; Brandon P. Combs; Christopher Moriates; Neel Shah; Deborah Grady
A columnist at theNew York Times asked readers, “Have you experiencedtoomuchmedicine?”Shereceivedmorethan1000 responses detailing examples ranging fromunnecessary testing and hospitalizations to useless office visits and specialist referrals.1 Patients are not the only ones worried about too muchmedicine: 42%of anational sampleofprimary carephysicians believe that patients in their own practice are receiving too muchmedical care.2 Too much medicine, or overuse, occurs in at least 3 contexts: when benefits from medical care are negligible, when thepotential for harmexceeds thepotential benefit,3 orwhen a fully informed patient would decide to forego the service. Examples of overuse include overtesting (eg, routinely ordering preoperative chest x-rays; see the Perspective in this issue4) and overtreatment (eg, coronary revascularization inpatientswith stable anginanot receivingoptimalmedical therapy). Spending on overuse is thought to substantially contribute to theunsustainablegrowth inUShealthcarecosts.5 Wastefulhealthcare is estimated tocost
JAMA Surgery | 2016
Corinna C. Zygourakis; Victoria Valencia; Christopher Moriates; Christy Boscardin; Sereina Catschegn; Alvin Rajkomar; Kevin J. Bozic; Kent Soo Hoo; Andrew N. Goldberg; Lawrence H. Pitts; Michael T. Lawton; R. Adams Dudley; Ralph Gonzales
750billionannually,6 limiting equitable access tonecessaryhealth care6 andcrowdingout spendingonotherpriorities suchaspublichealth, education, and valuable social programs.When passed on to our patients, health care costs can be financially catastrophic.7 The costs of overuse are not measured in dollars alone. Overtesting and overtreatment expose patients to potential harmsanddownstreamcomplications8—andoften lead tonet harm.Farbeyondcostconsciousness, theethicalcase foravoiding overuse, “first, do no harm,” is a powerful appeal to our professionalism.8 All thoughtful physicians want to minimize harms fromoveruse. The challenge is recognizingwhen an intervention is likely to represent overuse.
Academic Medicine | 2015
Christopher Moriates; Daniel Dohan; Joanne Spetz; George F. Sawaya
Importance Despite the significant contribution of surgical spending to health care costs, most surgeons are unaware of their operating room costs. Objective To examine the association between providing surgeons with individualized cost feedback and surgical supply costs in the operating room. Design, Setting, and Participants The OR Surgical Cost Reduction (OR SCORE) project was a single–health system, multihospital, multidepartmental prospective controlled study in an urban academic setting. Intervention participants were attending surgeons in orthopedic surgery, otolaryngology–head and neck surgery, and neurological surgery (n = 63). Control participants were attending surgeons in cardiothoracic surgery, general surgery, vascular surgery, pediatric surgery, obstetrics/gynecology, ophthalmology, and urology (n = 186). Interventions From January 1 to December 31, 2015, each surgeon in the intervention group received standardized monthly scorecards showing the median surgical supply direct cost for each procedure type performed in the prior month compared with the surgeon’s baseline (July 1, 2012, to November 30, 2014) and compared with all surgeons at the institution performing the same procedure at baseline. All surgical departments were eligible for a financial incentive if they met a 5% cost reduction goal. Main Outcomes and Measures The primary outcome was each group’s median surgical supply cost per case. Secondary outcome measures included total departmental surgical supply costs, case mix index–adjusted median surgical supply costs, patient outcomes (30-day readmission, 30-day mortality, and discharge status), and surgeon responses to a postintervention study-specific health care value survey. Results The median surgical supply direct costs per case decreased 6.54% in the intervention group, from
Academic Medicine | 2014
Andrew Levy; Neel Shah; Christopher Moriates; Vineet M. Arora
1398 (interquartile range [IQR],
Journal of Hospital Medicine | 2014
Christopher Moriates; Michelle Mourad; Maria Novelero; Robert M. Wachter
316-
JAMA Internal Medicine | 2014
Christopher Moriates; Neel Shah
5181) (10 637 cases) in 2014 to
JAMA | 2014
Leah Marcotte; Christopher Moriates; Arnold Milstein
1307 (IQR,
JAMA Internal Medicine | 2013
Christopher Moriates; Maria Novelero; Kathryn Quinn; Raman Khanna; Michelle Mourad
319-
AMA journal of ethics | 2015
Vineet M. Arora; Christopher Moriates; Neel Shah
5037) (11 820 cases) in 2015. In contrast, the median surgical supply direct cost increased 7.42% in the control group, from
Academic Medicine | 2017
Andrea N. Leep Hunderfund; Liselotte N. Dyrbye; Stephanie R. Starr; Jay Mandrekar; James M. Naessens; Jon C. Tilburt; Paul George; Elizabeth G. Baxley; Jed D. Gonzalo; Christopher Moriates; Susan Dorr Goold; Patricia A. Carney; Bonnie M. Miller; Sara Jo Grethlein; Tonya L. Fancher; Darcy A. Reed
712 (IQR,